MARKET

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.810
-0.060
-3.21%
After Hours: 1.760 -0.05 -2.76% 18:54 09/23 EDT
OPEN
2.100
PREV CLOSE
1.870
HIGH
2.160
LOW
1.730
VOLUME
3.07M
TURNOVER
--
52 WEEK HIGH
4.230
52 WEEK LOW
1.349
MARKET CAP
128.61M
P/E (TTM)
-4.0867
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1DHIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) yesterday presented data
GlobeNewswire · 13h ago
NKE, WDC among premarket gainers
SPI Energy (SPI) +56% after launching new EV Company.MediciNova (MNOV) +36% on positive intranasal COVID-19 vaccine data.vTv Therapeutics (VTVT) +20% on positive clinical study results supporting the safety and efficacy of TTP399.Athersys (ATHX) +13% after FDA grants RMAT
Seekingalpha · 13h ago
VTv Therapeutics +14% on positive TTP399 data in type 1 diabetes
VTv Therapeutics (VTVT) jumps 14% premarket after announcing data from the completed Phase 2 Simplici-T1 study that support the clinical potential of TTP399 as an oral adjunctive therapy in type 1 diabetes
Seekingalpha · 13h ago
vTv Therapeutics Highlights Presentation Of Additional Positive Clinical Study Results On Safety And Efficacy Of TTP399 As Adjunctive Therapy In Patients With Type 1 Diabetes
HIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.(NASDAQ:VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 study (NCT03335371)that support the clinical potential of
Benzinga · 14h ago
The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 21)
Benzinga · 1d ago
The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix
Biotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccine/antibody candidates catalyzing some strong moves.
Benzinga · 3d ago
An In-Depth Look At vTv Therapeutics
Today, we provide an in depth look at vTv Therapeutics. The company is developing two primary compounds.A good chunk of its stock is owned by Ronald Perelman who is often a frequent and large buyer of the shares.A full investment analysis follows in the paragraphs below.
Seekingalpha · 09/16 16:05
vTv Therapeutics To Present Additional Positive Clinical Study Results From Phase 2 Simplici-T1 Study Of TTP399 As Adjunctive Therapy For Patients With Type 1 Diabetes At EASD Virtual Meeting Sept. 21-25
HIGH POINT, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.(NASDAQ:VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral adjunctive therapy in
Benzinga · 09/16 11:37
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTVT. Analyze the recent business situations of VTV THERAPEUTICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTVT stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 53
Institutional Holdings: 3.79M
% Owned: 5.34%
Shares Outstanding: 71.05M
TypeInstitutionsShares
Increased
13
952.36K
New
27
493.28K
Decreased
4
168.22K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Director
Jeffrey Kindler
President/Chief Executive Officer
Stephen Holcombe
Chief Financial Officer/Executive Vice President
Rudy Howard
Director
Hersh Kozlov
Director
Edward Taibi
Independent Director
John Fry
Independent Director
Noel Spiegel
Independent Director
Howard Weiner
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.